Unenhanced diagnostic MR imaging–DWIBS mammography may detect false-positive X-ray screening mammograms.
Unenhanced diagnostic MR imaging (DWIBS mammography) may reduce the number of breast biopsies performed on women with suspicious X-ray screening mammograms, according to a study published in Radiology.
Researchers from Germany evaluated the ability of DWIBS mammography and unenhanced morphologic sequences to predict the likelihood of malignancy on suspicious screening X-ray mammograms, as compared with an abbreviated contrast material–enhanced breast MR imaging protocol and a full diagnostic breast MR imaging protocol. Unenhanced diagnostic MR imaging–DWIBS mammographies are shorter examinations (can be less than seven minutes) than full breast MR imaging protocol, which can take up to a half hour.[[{"type":"media","view_mode":"media_crop","fid":"42660","attributes":{"alt":"Sebastian Bickelhaupt, MD","class":"media-image media-image-right","id":"media_crop_7000558780930","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"4640","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 266px; width: 200px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"Sebastian Bickelhaupt, MD","typeof":"foaf:Image"}}]]
Fifty women (mean age, 57.1) participated in the prospective study. All had undergone mammograms, which showed suspicious findings, leading to recommendations for biopsies. Before having the biopsies, the women underwent full diagnostic contrast-enhanced MR imaging, which included DWIBS mammography. Two abbreviated protocols (APs) based on maximum intensity projections (MIPs) were evaluated regarding the potential to exclude malignancy: DWIBS (AP1) and subtraction images from the first postcontrast and the unenhanced series (AP2).
The results showed that 24 of the 50 women had a breast carcinoma:
Only pure microcalcification related ductal carcinoma in-situ (DCIS) without solid tumor, a very early stage of breast cancer, was not detected by any of the MR techniques.
“If the preliminary findings are confirmed, this approach could have a high potential to be used as an adjunct in the clarification process of unclear lesions on X-ray mammography in breast cancer screening,” lead author Sebastian Bickelhaupt, MD, said in a release. “This might help to reduce the number of invasive biopsies and the related anxiety in women who have suspicious findings at mammography.”
Bickelhaupt noted that more research is needed: “While the results so far are promising, the degree of evidence is currently not sufficient to recommend the method be implemented into the screening in a general setting.”
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.